Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospit...
Saved in:
Published in | BMC cancer Vol. 21; no. 1; pp. 1 - 807 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central Ltd
13.07.2021
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. Results A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P < 0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37-0.73, P < 0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22-0.67, P = 0.037). Conclusion ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab. Keywords: Breast cancer, Hormone receptor, HER2, Trastuzumab, Endocrine therapy, Escalation |
---|---|
AbstractList | Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P < 0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37-0.73, P < 0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22-0.67, P = 0.037). ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab. Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. Results A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P < 0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37–0.73, P < 0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22–0.67, P = 0.037). Conclusion ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab. Abstract Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. Results A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P < 0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group ( P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37–0.73, P < 0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively ( P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22–0.67, P = 0.037). Conclusion ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab. BACKGROUNDTrastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. METHODSER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. RESULTSA total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P < 0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37-0.73, P < 0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22-0.67, P = 0.037). CONCLUSIONER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab. Abstract Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. Results A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P < 0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37–0.73, P < 0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22–0.67, P = 0.037). Conclusion ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab. Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. Results A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P < 0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37-0.73, P < 0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22-0.67, P = 0.037). Conclusion ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab. Keywords: Breast cancer, Hormone receptor, HER2, Trastuzumab, Endocrine therapy, Escalation |
ArticleNumber | 807 |
Audience | Academic |
Author | Chen, Weiguo Shen, Kunwei Zhu, Li Chen, Xiaosong Li, Shuai Li, Yafen Wu, Jiayi Huang, Ou He, Jianrong |
Author_xml | – sequence: 1 givenname: Shuai surname: Li fullname: Li, Shuai – sequence: 2 givenname: Jiayi surname: Wu fullname: Wu, Jiayi – sequence: 3 givenname: Ou surname: Huang fullname: Huang, Ou – sequence: 4 givenname: Jianrong surname: He fullname: He, Jianrong – sequence: 5 givenname: Li surname: Zhu fullname: Zhu, Li – sequence: 6 givenname: Weiguo surname: Chen fullname: Chen, Weiguo – sequence: 7 givenname: Yafen surname: Li fullname: Li, Yafen – sequence: 8 givenname: Xiaosong surname: Chen fullname: Chen, Xiaosong – sequence: 9 givenname: Kunwei surname: Shen fullname: Shen, Kunwei |
BookMark | eNptkt9qFDEUxgdR7B99Aa8CgihlapJJJjNeCKVUWygIVa_DmeTMbspssiYZq76GL2y2W2pXJBeTnPy-L3MO30H12AePVfWC0WPGuvZtYrzrZE05q2knpazFo2qfCcVqLqh6_GC_Vx2kdE0pUx3tnlZ7jeCyVYzuV79PJ-edgYmYJUQwGaNL2ZlEwFtiXUJISMKcTVhhIs6Ts6sjMsRSzsSANxjfESDldg1FGTwZMN8genJ-dsWPyBqyQ58TyUWS0ZIbl5flUOTzr3kFw-07G7a-Z59VT0aYEj6_-x5WXz-cfTk9ry8_fbw4PbmsjeRU1INtLFDbKtPCYE1pTTEsIwHec2h6yYG1qm8tp3IUPZeWcWa5olyIBu0wNIfVxdbXBrjW6-hWEH_qAE7fFkJcaIhlFhPqDmHko-17aY0AOw6tpNKAxJYygY0oXu-3Xut5WKE1pY8I047p7o13S70I33XHVadoXwxe3xnE8G3GlPXKJYPTBB7DnDSXkknVtmKDvvwHvQ5z9GVUG6rhQnas_UstoDTg_BjKu2Zjqk9axZtGcbb57-P_UGVZXDlT8ja6Ut8RvNkRFCbjj7yAOSV98flql331gF0iTHmZwjRnF3zaBfkWNDGkFHG8HxyjepN1vc26LlnXt1nXovkDUbfvnQ |
CitedBy_id | crossref_primary_10_1186_s12885_022_10136_y |
Cites_doi | 10.1007/s12094-019-02163-2 10.1200/JCO.2006.09.2775 10.1126/science.2470152 10.1016/S1470-2045(13)70384-X 10.1200/JCO.2009.25.6529 10.1371/journal.pmed.1000279 10.1016/S1470-2045(14)70080-4 10.1001/jama.2018.19323 10.1200/JCO.19.00126 10.1016/j.ejca.2019.05.004 10.1056/NEJMoa1404037 10.1056/NEJMoa1803164 10.1186/1471-2407-13-390 10.1056/NEJMoa053028 10.1200/JCO.2018.77.8738 10.1200/JCO.2014.55.5730 10.1056/NEJMoa1412379 10.1016/j.ejca.2017.10.033 10.1007/s10549-007-9660-2 10.1093/annonc/mdt287 10.1200/JCO.2013.50.9984 10.1016/S0140-6736(16)32616-2 10.1200/JCO.2015.65.9573 10.1200/JCO.19.00066 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
Copyright_xml | – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
DBID | AAYXX CITATION ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s12885-021-08555-4 |
DatabaseName | CrossRef Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2407 |
EndPage | 807 |
ExternalDocumentID | oai_doaj_org_article_8eaf2fd995dc4adfb6505ca5e6014e34 A672337214 10_1186_s12885_021_08555_4 |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AFGXO ABVAZ AFNRJ 7TO 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c5204-bd3da0d67c6abdc78071e128a292a3952a16796d205f4925d121d2702443edbb3 |
IEDL.DBID | RPM |
ISSN | 1471-2407 |
IngestDate | Tue Oct 22 15:13:42 EDT 2024 Tue Sep 17 21:29:23 EDT 2024 Sat Oct 05 05:22:47 EDT 2024 Thu Oct 10 16:19:35 EDT 2024 Thu Feb 22 23:50:24 EST 2024 Fri Feb 02 04:19:14 EST 2024 Thu Aug 01 19:29:20 EDT 2024 Tue Aug 20 22:12:54 EDT 2024 Thu Sep 12 17:02:30 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5204-bd3da0d67c6abdc78071e128a292a3952a16796d205f4925d121d2702443edbb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278709/ |
PMID | 34256710 |
PQID | 2553245816 |
PQPubID | 44074 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_8eaf2fd995dc4adfb6505ca5e6014e34 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8278709 proquest_miscellaneous_2551576649 proquest_journals_2553245816 gale_infotracmisc_A672337214 gale_infotracacademiconefile_A672337214 gale_incontextgauss_ISR_A672337214 gale_healthsolutions_A672337214 crossref_primary_10_1186_s12885_021_08555_4 |
PublicationCentury | 2000 |
PublicationDate | 20210713 |
PublicationDateYYYYMMDD | 2021-07-13 |
PublicationDate_xml | – month: 7 year: 2021 text: 20210713 day: 13 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | BMC cancer |
PublicationYear | 2021 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | AG Waks (8555_CR2) 2019; 321 F Bray (8555_CR1) 2018; 68 DJ Slamon (8555_CR5) 1989; 244 HA Kim (8555_CR27) 2020; 38 HJ Burstein (8555_CR22) 2016; 34 Y Tong (8555_CR13) 2018; 89 PA Francis (8555_CR25) 2018; 379 F Perrone (8555_CR26) 2019; 118 SM Tolaney (8555_CR11) 2019; 37 O Pagani (8555_CR24) 2014; 371 SE Jones (8555_CR10) 2013; 14 AC Wolff (8555_CR16) 2013; 31 H Joensuu (8555_CR20) 2006; 354 DJ Slamon (8555_CR4) 1987; 10 L Gianni (8555_CR21) 2014; 15 D Cameron (8555_CR7) 2017; 389 AC Wolff (8555_CR17) 2018; 36 F Montemurro (8555_CR3) 2013; 24 K Chen (8555_CR18) 2019; 22 ME Hammond (8555_CR14) 2010; 28 AC Wolff (8555_CR15) 2007; 25 FM Blows (8555_CR19) 2010; 7 EA Perez (8555_CR8) 2014; 32 R Lisa (8555_CR6) 2008; 109 D Slamon (8555_CR9) 2012; 366 PA Francis (8555_CR23) 2015; 372 X Chen (8555_CR12) 2013; 13 |
References_xml | – volume: 22 start-page: 576 issue: 4 year: 2019 ident: 8555_CR18 publication-title: Clin Transl Oncol doi doi: 10.1007/s12094-019-02163-2 contributor: fullname: K Chen – volume: 25 start-page: 118 year: 2007 ident: 8555_CR15 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.2775 contributor: fullname: AC Wolff – volume: 244 start-page: 707 issue: 4905 year: 1989 ident: 8555_CR5 publication-title: Science doi: 10.1126/science.2470152 contributor: fullname: DJ Slamon – volume: 14 start-page: 1121 issue: 11 year: 2013 ident: 8555_CR10 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70384-X contributor: fullname: SE Jones – volume: 28 start-page: 2784 issue: 16 year: 2010 ident: 8555_CR14 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.6529 contributor: fullname: ME Hammond – volume: 10 start-page: 334 issue: 4785 year: 1987 ident: 8555_CR4 publication-title: Science contributor: fullname: DJ Slamon – volume: 7 issue: 5 year: 2010 ident: 8555_CR19 publication-title: PLoS Med doi: 10.1371/journal.pmed.1000279 contributor: fullname: FM Blows – volume: 15 start-page: 640 issue: 6 year: 2014 ident: 8555_CR21 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70080-4 contributor: fullname: L Gianni – volume: 321 start-page: 288 issue: 3 year: 2019 ident: 8555_CR2 publication-title: JAMA doi: 10.1001/jama.2018.19323 contributor: fullname: AG Waks – volume: 38 start-page: 434 issue: 5 year: 2020 ident: 8555_CR27 publication-title: J Clin Oncol. doi: 10.1200/JCO.19.00126 contributor: fullname: HA Kim – volume: 118 start-page: 178 year: 2019 ident: 8555_CR26 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2019.05.004 contributor: fullname: F Perrone – volume: 371 start-page: 107 issue: 2 year: 2014 ident: 8555_CR24 publication-title: N Engl J Med doi: 10.1056/NEJMoa1404037 contributor: fullname: O Pagani – volume: 379 start-page: 122 issue: 2 year: 2018 ident: 8555_CR25 publication-title: N Engl J Med doi: 10.1056/NEJMoa1803164 contributor: fullname: PA Francis – volume: 13 start-page: 390 issue: 1 year: 2013 ident: 8555_CR12 publication-title: BMC Cancer doi: 10.1186/1471-2407-13-390 contributor: fullname: X Chen – volume: 354 start-page: 809 issue: 8 year: 2006 ident: 8555_CR20 publication-title: N Engl J Med doi: 10.1056/NEJMoa053028 contributor: fullname: H Joensuu – volume: 36 start-page: 2105 issue: 20 year: 2018 ident: 8555_CR17 publication-title: J Clin Oncol doi: 10.1200/JCO.2018.77.8738 contributor: fullname: AC Wolff – volume: 32 start-page: 3744 issue: 33 year: 2014 ident: 8555_CR8 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.55.5730 contributor: fullname: EA Perez – volume: 372 start-page: 436 issue: 5 year: 2015 ident: 8555_CR23 publication-title: N Engl J Med doi: 10.1056/NEJMoa1412379 contributor: fullname: PA Francis – volume: 89 start-page: 9 year: 2018 ident: 8555_CR13 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.10.033 contributor: fullname: Y Tong – volume: 109 start-page: 351 issue: 2 year: 2008 ident: 8555_CR6 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-007-9660-2 contributor: fullname: R Lisa – volume: 24 start-page: 2715 issue: 11 year: 2013 ident: 8555_CR3 publication-title: Ann Oncol doi: 10.1093/annonc/mdt287 contributor: fullname: F Montemurro – volume: 31 start-page: 3997e4013 issue: 31 year: 2013 ident: 8555_CR16 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.50.9984 contributor: fullname: AC Wolff – volume: 389 start-page: 1195 issue: 10075 year: 2017 ident: 8555_CR7 publication-title: Lancet doi: 10.1016/S0140-6736(16)32616-2 contributor: fullname: D Cameron – volume: 366 start-page: 1273 issue: 7 year: 2012 ident: 8555_CR9 publication-title: N Engl J Med contributor: fullname: D Slamon – volume: 68 start-page: 394 issue: 6 year: 2018 ident: 8555_CR1 publication-title: CA: A Cancer J Clin contributor: fullname: F Bray – volume: 34 start-page: 1689 issue: 14 year: 2016 ident: 8555_CR22 publication-title: J Clin Oncol doi: 10.1200/JCO.2015.65.9573 contributor: fullname: HJ Burstein – volume: 37 start-page: 1868 issue: 22 year: 2019 ident: 8555_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.19.00066 contributor: fullname: SM Tolaney |
SSID | ssj0017808 |
Score | 2.386633 |
Snippet | Abstract
Background
Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with... Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab,... Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to... BACKGROUNDTrastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab,... Abstract Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with... |
SourceID | doaj pubmedcentral proquest gale crossref |
SourceType | Open Website Open Access Repository Aggregation Database |
StartPage | 1 |
SubjectTerms | Breast cancer Cancer therapies Chemotherapy Drug therapy Endocrine therapy ErbB-2 protein Escalation HER2 Hormone receptor Medical prognosis Menopause Menstruation Metastasis Monoclonal antibodies Multivariate analysis Patient outcomes Patients Prognosis Radiation therapy Regression analysis Surgery Survival Targeted cancer therapy Trastuzumab Tumors Womens health |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4ikCBQxC4rCKmvgVh1tBWy1IcFio1JvlV6BSyaJmc-nf6B9mxvGuGjhw4bjrL9rNzNiZL575TMgbnkTYpCpF64GgyE6VTmteqhA1a4OvK5cKZL-o1an4dCbPbhz1hTVhkzzwZLgjHW3HutC2MnhhQ-cgpZDeyghMQkQ-KYHWckem8v5Boyu9a5HR6miAVVhjJzK-DpRSlmL2GEpq_X-vyX_WSd548JzcI3dzxkiPp396n9yK_QNy-3PeE39IrrO05wX1c_FlavtA8wYM3YxbiK040POeLtcL6rAYfUs9Ov3yHbXU7w8kpLl2i66Wa7agWXl1oKkmPQaKr27hA1w-Xo0_rUu_g9hyj31ETk-W3z6synzUQuklq0TpAg-2CqrxyrrgwXxNHcFolrXM8lYyi9s1KoBbO5QzDDWrA7ayCcFjcI4_Jgf9po9PCGVVB2lMBMbeMBGCsx1QLq9t1XGvPa8LsthZ3vyaFDVMYiJamclPBvxkkp-MKMh7dM4eiWrY6QuIEZNjxPwrRgryEl1rptbS_Zw2x6phnAMHBsTrhEBFjB5Lbr7bcRjMx6_rGehtBnUbsLK3uYMB7htFtGbIwxkSpqyfD-9izOQlYzDA7SC5lbpWBXm1H8YrsQyuj5sxYWogiEq0BWlmsTkz0HykP_-RZMM1w8W5ffo_LPqM3GFpNjVlzQ_JwfZyjM8hO9u6F2ki_gbJyThj priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96B-KL-Imrp0YRfFjKtflq6ovcyR6r4CGrB_cW0iQ9D7Q9t9sX_w3_YWey2WoVfGwzbelMZjKTmfmFkJc8grBJlYnKQYAiG5XVWvNM-aBZ5V2R17FA9lQtz8T7c3meNtz6VFa5s4nRUPvO4R75Ibi-sPZLXag3V98zPDUKs6vpCI3rZJ8VAtO0-8eL04-rMY9Q6lzvWmW0OuzBGmvsSMZtQSllJibLUUTt_9c2_10v-ccCdHKb3EqeIz3aivoOuRbau-TGh5Qbv0d-JojPr9RNQZipbT1NiRjaDRv439DTy5YuVnNaY1H6hjoU_vo1tdSNBxPSVMNFl4sVm9OEwNrTWJsePMUtXLiAx4cfwzdbx-8gbTbS3idnJ4vPb5dZOnIhc5LlIqs99zb3qnTK1t4B-8oiANMsq5jllWQW0zbKg3gbhDX0BSs8trQJwYOva_6A7LVdGx4SyvIG3JkAkXvJhPe1bSD0ctrmDXfa8WJG5jvOm6stsoaJEYlWZisnA3IyUU5GzMgxCmekRFTseKNbX5ikZEYH27DGV5X0Tljf1OB-SmdlgKhTBA4veYaiNdsW01G3zZEqGecQCwPFi0iByBgtlt5c2KHvzbtPqwnRq0TUdMBlZ1MnA_w3gmlNKA8mlKC6bjq8m2MmmY7e_J7oM_J8HMYnsRyuDd0QaQoIFJWoZqSczM0Jg6Yj7eWXCB-uGRrp6tH_P_6Y3GRRT8qs4Adkb7MewhPwvzb106RkvwDL5DAH priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LixNBEG7WFcSL-MToqq0IHsJopl_TI4issksU1kM0sLemX7O7sE40kwH1b_iHrep0oqMLHpP-ZkLq0dM1VfUVIU95ImGTqhC1hwBFNqpwWvNChahZHXw5calA9oOazsX7Y3m8QzbjjrIAuwtDO5wnNV-eP__29ftrcPhXyeG1etHBHquxzxhf9kkpC3GJXGaCC7T4I_E7q1DpNKGuhA0ZswrVponmwnsMHlSJz__fXfvvSso_Hk2H18m1fKak-2sjuEF2YnuTXDnKWfNb5Gcm_zynfkjPTG0baE7R0EW_AuuLHT1r6cFsTB2Wq6-oR7NYvqSW-u3IQpqru-j0YMbGNHOzdjRVrcdA8eUufIDL-x_9Z-vS7yC22GJvk_nhwae30yIPYyi8ZBNRuMCDnQRVeWVd8CDKqowgNMtqZnktmcWEjgqg-AYJD0PJyoDNbkLwGJzjd8huu2jjXULZpIGDToSYvmIiBGcbCMq8tpOGe-15OSLjjeTNlzXnhkmxilZmrScDejJJT0aMyBtUzhaJfNnpi8XyxGT3MzrahjWhrmXwwobGwcFUeisjxKMicrjJI1StWTefbr3e7KuKcQ5RMiCeJARyZrRYlHNi-64z7z7OBqBnGdQsQMre5h4H-N9IszVA7g2Q4NR-uLyxMbPxCQPRHxx_pS7ViDzeLuOVWCjXxkWfMCWEkErUI1INbHMgoOFKe3aaiMU1w-27vvdfYdwnV1lylaoo-R7ZXS37-AAOZyv3MHncL2BKNNI priority: 102 providerName: Scholars Portal |
Title | Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients |
URI | https://www.proquest.com/docview/2553245816 https://search.proquest.com/docview/2551576649 https://pubmed.ncbi.nlm.nih.gov/PMC8278709 https://doaj.org/article/8eaf2fd995dc4adfb6505ca5e6014e34 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe2ISFeEJ-iMIpBSDxUWRM7dhze1qlTQeo0FSZNvFj-yqi0plPTvPBv8A9zdp1qgTdeIqU-t43vzrmzf_czQh9pIGFjPMlLAwkKq3iihaAJt06Q0pos1QEge8FnV_nXa3Z9gFhXCxNA-0YvT-rb1Um9_BmwlXcrM-5wYuPL-Zkg3szK8SE6LCjtUvS4dVCIVHTVMYKPG5iAhS9C9iuBjLHEn8RDwVJ54atm772MAmf_vzPz32jJe6-f8yfocYwb8enu_z1FB65-hh7O4874c_Q7EnzeYtOnYMaqtjhuw-B1uwULcw1e1ni6GGHtIelbbLzqN5-xwmZ_LCGOCC48my7ICEf-1QYHZLqz2C_gwg10b3-1K6XD73jZZC_7Al2dT7-fzZJ44EJiGEnzRFtqVWp5YbjS1sBIFpmD8VOkJIqWjCi_acMtKLfypIY2I5n1BW15Tp3Vmr5ER_W6dq8QJmkFwYyDvL0gubVaVZB4GaHSihphaDZAo27k5d2OV0OGfERwuVOZBJXJoDKZD9DEK2cv6TmxwwfrzY2MliGFUxWpbFkya3JlKw3BJzOKOcg5c0fhS9551cpdgenes-UpLwilkAmDxIcg4Xkxag-8uVFt08gv3xY9oU9RqFrDKBsV6xjguT2VVk_yuCcJjmv6zZ2NyThxNBIyPAhxmcj4AL3fN_ueHgxXu3UbZDJIE3leDlDRs83eAPVbwJcCeXj0ndf_3fMNekSCNxVJRo_R0XbTurcQmG31ENzxuhiiB5PpxeViGJY34DrPBVwXkx_D4Kh_ALjhPQs |
link.rule.ids | 230,315,733,786,790,870,891,2115,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSMAF8VQXCjUIicMqauJXHC6ooK220PawtNLeLL9SKkFSNpsLf4M_zNjrDQQkjom_JMqMZ-yxZz4j9JpGEjYuMlZZCFB4LTIjJc2E85JUzha5iQmyZ2J-wT4u-TItuHUprXLrE6Ojdq0Na-QHMPWFsZ_LQry7_p6FU6PC7mo6QuMmusUoZaGfl8sh4CpKmcttoYwUBx34YhnqkcOiIOc8Y6PBKHL2_-uZ_86W_GP4ObqP7qV5Iz7cKPoBuuGbh-j2adoZf4R-JoLPr9iOKZixbhxO2zC47dfwt77DVw2eLabYhJT0NbZB9au3WGM7HEuIUwYXns8WZIoT_2qHY2a6dzgs4MIFPN7_6L9pE78TsNmAfYwujmbnH-ZZOnAhs5zkLDOOOp07UVqhjbMgvrLwIDRNKqJpxYkOmzbCgXLrQGroClK4UNDGGPXOGPoE7TRt43cRJnkNkxkPcXtJmHNG1xB4WanzmlppaTFB063k1fWGV0PFeEQKtdGTAj2pqCfFJuh9UM6ADJzY8Ua7ulTJxJT0uia1qyruLNOuNjD55FZzDzEn8xResh9UqzYFpoNlq0NREkohEgbEq4gIvBhNSLy51H3XqePPixHoTQLVLUjZ6lTHAP8dqLRGyL0REgzXjpu3fUwlx9Gp3918gl4OzeHJkAzX-LaPmALCRMGqCSpHfXMkoHFLc_UlkodLElx09fT_H99Hd-bnpyfq5Pjs0zN0l0SbKbOC7qGd9ar3z2EmtjYvorn9AiBmMY4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVgSBMvfKMVBjMIiYcqbWInjsPbGJ06YNNUmDTxYvkro2JNq6Z52d_gD3PtOlUz3vbY-DhN4mPHNz73GKEP1JuwZSxKCw0BSlaySHFOI2YsJ4XRSay8QPaMjS_Sr5fZ5dZWX160r9V0UF3PBtX0t9dWLmZ62OrEhuenR5w4mhXDhSmH99ED6LMkbwP1sICQ85i3OTKcDWsYhrlLRXbfA7Msi9x-PBT4ynKXO7v1SvLO_f-Pz7c1k1svoePH6Fd7-WvtyZ9Bs1IDfXPL2fFO9_cEPQpTU3y4hjxF92z1DO2ehsX35-hv8BC9xrrr8oxlZXBY6cHzZgUktjWeVng06WPlVO8rrB27lp-wxHqz8yEOIjE8Hk1IHweL1xp78bs12H0jhh9QvblpZlL5_3HYaIN9gS6ORz-PxlHY0yHSGYnTSBlqZGxYrplURkMz5YmFxpGkIJIWGZFuXYgZ4E_pfBNNQhLjcubSlFqjFH2Jdqp5ZfcQJnEJ8yVrFclJaoySJcR2msu4pJprmvRQv21WsVhbdwgf8nAm1nwQwAfh-SDSHvrsWn6DdLbb_sB8eSVC4whuZUlKUxSZ0ak0pYL5baZlZiGsTS2Fkxw43oh1Dutm8BCHLCeUQrANiPce4aw3KqftuZJNXYuTH5MO6GMAlXN4ylqGVAm4b-fW1UHud5AwNuhucUtgEcamWkAQCbPojCesh95til1Np7er7LzxmAQiUZYWPZR3iN95QN0SoLP3Jw_0fXXnmgdo9_zLsfh-cvbtNXpIfK_No4Tuo53VsrFvYBq4Um99h_8HaZJcKw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+characteristics+and+disease+outcomes+in+ER%2B+breast+cancer%3A+a+comparison+between+HER2%2B+patients+treated+with+trastuzumab+and+HER2-+patients&rft.jtitle=BMC+cancer&rft.au=Li%2C+Yafen&rft.au=He%2C+Jianrong&rft.au=Chen%2C+Weiguo&rft.au=Shen%2C+Kunwei&rft.date=2021-07-13&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-021-08555-4&rft.externalDBID=n%2Fa&rft.externalDocID=A672337214 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |